Cytokinetics, Incorporated (CYTK)

Cytokinetics Statistics

Total Valuation

Cytokinetics has a market cap or net worth of $5.81 billion. The enterprise value is $5.78 billion.

Market Cap	5.81B
Enterprise Value	5.78B

Important Dates

The last earnings date was Wednesday, November 6, 2024, after market close.

Earnings Date	Nov 6, 2024
Ex-Dividend Date	n/a

Share Statistics

Cytokinetics has 118.01 million shares outstanding. The number of shares has increased by 12.36% in one year.

Current Share Class	118.01M
Shares Outstanding	118.01M
Shares Change (YoY)	+12.36%
Shares Change (QoQ)	+7.73%
Owned by Insiders (%)	0.48%
Owned by Institutions (%)	116.98%
Float	117.41M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	1,795.81
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.28

Current Ratio	9.28
Quick Ratio	9.22
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-6.48

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-30.13%
Return on Capital (ROIC)	-54.45%
Revenue Per Employee	$7,610
Profits Per Employee	-$1.36M
Employee Count	423
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +53.70% in the last 52 weeks. The beta is 0.78, so Cytokinetics's price volatility has been lower than the market average.

Beta (5Y)	0.78
52-Week Price Change	+53.70%
50-Day Moving Average	53.86
200-Day Moving Average	59.68
Relative Strength Index (RSI)	39.06
Average Volume (20 Days)	1,284,580

Short Selling Information

The latest short interest is 15.69 million, so 13.29% of the outstanding shares have been sold short.

Short Interest	15.69M
Short Previous Month	15.54M
Short % of Shares Out	13.29%
Short % of Float	13.36%
Short Ratio (days to cover)	16.41

Income Statement

In the last 12 months, Cytokinetics had revenue of $3.22 million and -$576.40 million in losses. Loss per share was -$5.38.

Revenue	3.22M
Gross Profit	-327.54M
Operating Income	-524.63M
Pretax Income	-545.28M
Net Income	-576.40M
EBITDA	-511.14M
EBIT	-524.63M
Loss Per Share	-$5.38

Balance Sheet

The company has $1.01 billion in cash and $908.23 million in debt, giving a net cash position of $103.47 million or $0.88 per share.

Cash & Cash Equivalents	1.01B
Total Debt	908.23M
Net Cash	103.47M
Net Cash Per Share	$0.88
Equity (Book Value)	-13.91M
Book Value Per Share	-0.12
Working Capital	908.79M

Cash Flow

In the last 12 months, operating cash flow was -$404.36 million and capital expenditures -$2.69 million, giving a free cash flow of -$407.05 million.

Operating Cash Flow	-404.36M
Capital Expenditures	-2.69M
Free Cash Flow	-407.05M
FCF Per Share	-$3.45

Margins

Gross Margin	n/a
Operating Margin	-16,297.79%
Pretax Margin	-17,906.24%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-12,803.89%

Dividends & Yields

Cytokinetics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.36%
Shareholder Yield	-12.36%
Earnings Yield	-9.80%
FCF Yield	-6.92%

Analyst Forecast

The average price target for Cytokinetics is $83.67, which is 69.98% higher than the current price. The consensus rating is "Buy".

Price Target	$83.67
Price Target Difference	69.98%
Analyst Consensus	Buy
Analyst Count	16
Revenue Growth Forecast (5Y)	193.39%
EPS Growth Forecast (5Y)	n/a

Stock Splits

The last stock split was on June 25, 2013. It was a reverse split with a ratio of 0.1666666:1.

Last Split Date	Jun 25, 2013
Split Type	Reverse
Split Ratio	0.1666666:1

Scores

Cytokinetics has an Altman Z-Score of -0.42 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.42
Piotroski F-Score	2